Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-28
2011-06-28
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C530S350000
Reexamination Certificate
active
07968520
ABSTRACT:
This invention features methods and compositions useful for treating and diseases caused by a dysregulation of the BMP/GDF branch of the TGF-β signaling pathway. Also disclosed are methods for identifying compounds useful for such therapy.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5571714 (1996-11-01), Dasch et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5719120 (1998-02-01), Letarte et al.
patent: 5830847 (1998-11-01), Letarte et al.
patent: 6015693 (2000-01-01), Letarte et al.
patent: 2003/0153519 (2003-08-01), Kay et al.
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0170891 (2003-09-01), McSwiggen
patent: 2003/0180756 (2003-09-01), Shi et al.
patent: WO-9424314 (1994-10-01), None
patent: WO-9512608 (1995-05-01), None
patent: WO-0177350 (2001-10-01), None
patent: WO-02051438 (2002-07-01), None
patent: 02/098444 (2002-12-01), None
patent: WO-02098444 (2002-12-01), None
patent: WO-03004615 (2003-01-01), None
patent: 03/089608 (2003-10-01), None
patent: WO-03089608 (2003-10-01), None
patent: 2004/003150 (2004-01-01), None
patent: 2004/004750 (2004-01-01), None
patent: WO-2004004750 (2004-01-01), None
patent: 2004/016606 (2004-02-01), None
patent: WO-2004016606 (2004-02-01), None
patent: 2005/028517 (2005-03-01), None
patent: WO-2005028517 (2005-03-01), None
ATCC Global Bioresource Center, ATCC No. CL-101, (2010).
ATCC Global Bioresource Center, ATCC No. CRL-1573, (2010).
Augsburger et al., “BMPs as Mediators of Roof Plate Repulsion of Commissural Neurons”,Neuron., 24:127-141 (1999).
Babitt et al., “Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression”,Nat. Genet., 38(5):531-539 (2006).
Babitt et al., “Repulsive Guidance Molecule (RGMa), a DRAGON Homologue, Is a Bone Morphogenetic Protein Co-receptor”,J. Biol. Chem., 280(33):29820-29827 (2005).
Balemans et al., “Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators”,Dev. Biol. 250:231-250 (2002).
Barcellos-Hoff et al., “Transforming growth factor-β and breast cancer: Mammary gland development”,Breast Cancer Res., 2:92-99 (2000).
Barthelemy et al., “The Expression of Saporin, a Ribosome-inactivating Protein from the PlantSaponaria officinalis, inEscherichia coli”, J. Biol. Chem., 268(9):6541-6548 (1993).
Brinks et al., “The Repulsive Guidance Molecule RGMa Is Involved in the Formation of Afferent Connections in the Dentate Gyrus”,J. Neurosci., 24(15):3862-3869 (2004).
Brown et al., “Requirement of Type III TGF-β Receptor for Endocardial Cell Transformation in the Heart”,Science, 283:2080-2082 (1999).
Brunet et al., “Noggin, Cartilage Morphogenesis, and Joint Formation in the Mammalian Skeleton”,Science, 280:1455-1457 (1998).
Chappuis-Flament et al., “Multiple cadherin extracellular repeats mediate homophilic binding and adhesion”,J. Cell Biol., 154(1):231-243 (2001).
Chen et al., “Differential Roles for Bone Morphogenetic Protein (BMP) Receptor Type IB and IA in Differentiation and Specification of Mesenchymal Precursor Cells to Osteoblast and Adipocyte Lineages”,J. Cell Bio., 142(1):295-305 (1998).
Cheng et al., “EGF-CFC proteins are essential coreceptors for the TFG-β signals Vg1 and GDF1”,Genes Dev., 17:31-36 (2003).
Clarke et al., “Müllerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 expression”,Mol. Endocrinol., 15:946-959 (2001).
Costigan et al., “Heat Shock Protein 27: Developmental Regulation and Expression after Peripheral Nerve Injury”,J. Neurosci., 18(15):5891-5900 (1998).
Dagerlind et al., “Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry”,Histochemistry, 98:39-49 (1992).
Database TrEMBL Q95XN8, Du, et al., “The sequence ofC. eleganscosmid Y71G12B”, Dec. 2001, 100% identical to SEQ ID No. 18.
Database, Auffray, C., et al., NCBI Accession No. CAB98207, Jul. 2000, 100% identical to SEQ ID No. 10 over 446 residues.
Database, WPI Week 2001 Derwent Publications Ltd., 2001-317422 XP002416009 & CN 1 284 380 A (Inst Hematology Chinese Acad Medical Sci) Feb. 21, 2001.
De Angelis et al., “The acid-stress response inLactobacillus sanfranciscensisCB1”,Microbiol., 147:1863-1873 (2001).
del Re et al., “In the Absence of Type III Receptor, the Transforming Growth Factor (TGF)-β Type II-B Receptor Requires the Type I Receptor to Bind TGF-β2”,J. Biol. Chem., 279(21):22765-22772 (2004).
Dennler et al., “Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene”,EMBO J., 17(11):3091-3100 (1998).
Derynck et al., “Smad-dependent and Smad-independent pathways in TGF-β family signalling”,Nature, 425:577-584 (2003).
Dewulf et al., “Distinct Spatial and Temporal Expression Patterns of Two Type I Receptors for Bone Morphogenetic Proteins during Mouse Embryogenesis”,Endocrinol., 136(6):2652-2663 (1995).
Edwards et al., “Bone Morphogenetic Proteins in the Development and Healing of Synovial Joints”,Semin. Arthritis Rheum., 31(1):33-42 (2001).
Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”,Nature, 411:494-498 (2001).
Erickson et al., “Analysis of spatial and temporal expression patterns of bone morphogenetic protein family members in the rat uterus over the estrous cycle”,J. Endocrinol., 182:203-217 (2004).
Faber et al., “Bmp signaling is required for development of primary lens fiber cells”,Dev., 129:15:3727-3737 (2002).
Fabre et al., “The Booroola mutation in sheep is associated with an alteration of the bone morphogenetic protein receptor-IB functionality”,J. Endocrinol., 177:435-444 (2003).
Feng et al., “Generation and in Vitro Differentiation of a Spermatogonial Cell Line”,Science, 297:392-395 (2002).
Friedmann, T., “Progress Toward Human Gene Therapy”,Science, 244:1275-1281 (1989).
Frolik et al., “Characterization of a Membrane Receptor for Transforming Growth Factor-β in Normal Rat Kidney Fibroblasts”,J. Biol. Chem., 259(17):10995-11000 (1984).
Gallaway et al., “Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner”,Nat. Genet., 25:279-283 (2000).
Ge et al., “RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription”,Proc. Natl. Acad. Sci. U.S.A., 100(5):2718-2723 (2003).
GenBank Accession No. CAA48885, dated Apr. 18, 2005.
GenBank Accession No: NM 177740, dated Aug. 5, 2010.
Goggins et al., “Genetic Alterations of the Transforming Growth Factor β Receptor Genes in Pancreatic and Biliary Adenocarcinomas”,Cancer Res., 58:5329-5332 (1998).
Gong et al., “Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis”,Nat. Genet., 21:302-304 (1999).
Grady et al., “Mutational Inactivation of Transforming Growth Factor β Receptor Type II in Microsatellite Stable Colon Cancers”,Cancer Res., 59:320-324 (1999).
Gray et al., “Cripto forms a complex with activin and type II activin receptors and can block activin signaling”,Proc. Natl. Acad. Sci. U.S.A., 100(9):5193-5198 (2003).
Groppe et al., “Structural basis of BMP signalling inhibition by the cystine knot protein Noggin”,Nature, 420:636-642 (2002).
Hannon, G. J., “RNA interference”,Nature, 418:244-251 (2002).
Hata et al., “Smad6 inhibits BMP/Smad
Samad Tarek A.
Woolf Clifford J.
Lockard Jon M
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Saoud Christine J
The General Hospital Corporation
LandOfFree
Chimeric DRG11-responsive (DRAGON) polypetides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric DRG11-responsive (DRAGON) polypetides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric DRG11-responsive (DRAGON) polypetides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668138